- Home
- PSTX
as 07-26-2024 4:00pm EST
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 285.1M | IPO Year: | 2020 |
| Target Price: | $14.67 | AVG Volume (30 days): | 514.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $4.27 | Next Earning Date: | 08-06-2024 |
| Revenue: | $82,502,000 | Revenue Growth: | -40.82% |
| Revenue Growth (this year): | 17.26% | Revenue Growth (next year): | -48.46% |
Latest Poseida Therapeutics Inc. News
PSTX Breaking Stock News: Dive into PSTX Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
PR Newswire
25 days ago
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
Motley Fool
2 months ago
BigBear.ai Stock: Buy, Sell, or Hold?
AFP
2 months ago
Indonesia's first Olympic gymnast encourages others to 'dream higher'
Motley Fool
2 months ago
Where Will CrowdStrike Stock Be in 1 Year?
GuruFocus.com
2 months ago
Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp
GuruFocus.com
2 months ago
Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...
Simply Wall St.
2 months ago
A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)
Compare PSTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PSTX Poseida Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.